Richard S. Finn, UCLA Medical Center, USA
Provided an on-site interpretation of the IMbrave152 study at ESMO: A new breakthrough in first-line treatment for liver cancer! The triple-therapy regimen significantly improved overall survival (OS) and progression-free survival (PFS), with a favorable safety profile, poised to reshape the treatment landscape for advanced hepatocellular carcinoma (HCC).